Gut microbiome and atrial fibrillation—results from a large population-based study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Dokumenter
- Fulltext
Forlagets udgivne version, 994 KB, PDF-dokument
Background: Atrial fibrillation (AF) is an important heart rhythm disorder in aging populations. The gut microbiome composition has been previously related to cardiovascular disease risk factors. Whether the gut microbial profile is also associated with the risk of AF remains unknown. Methods: We examined the associations of prevalent and incident AF with gut microbiota in the FINRISK 2002 study, a random population sample of 6763 individuals. We replicated our findings in an independent case–control cohort of 138 individuals in Hamburg, Germany. Findings: Multivariable-adjusted regression models revealed that prevalent AF (N = 116) was associated with nine microbial genera. Incident AF (N = 539) over a median follow-up of 15 years was associated with eight microbial genera with false discovery rate (FDR)-corrected P < 0.05. Both prevalent and incident AF were associated with the genera Enorma and Bifidobacterium (FDR-corrected P < 0.001). AF was not significantly associated with bacterial diversity measures. Seventy-five percent of top genera (Enorma, Paraprevotella, Odoribacter, Collinsella, Barnesiella, Alistipes) in Cox regression analyses showed a consistent direction of shifted abundance in an independent AF case–control cohort that was used for replication. Interpretation: Our findings establish the basis for the use of microbiome profiles in AF risk prediction. However, extensive research is still warranted before microbiome sequencing can be used for prevention and targeted treatment of AF. Funding: This study was funded by European Research Council, German Ministry of Research and Education, Academy of Finland, Finnish Medical Foundation, and the Finnish Foundation for Cardiovascular Research, the Emil Aaltonen Foundation, and the Paavo Nurmi Foundation.
| Originalsprog | Engelsk |
|---|---|
| Artikelnummer | 104583 |
| Tidsskrift | EBioMedicine |
| Vol/bind | 91 |
| ISSN | 2352-3964 |
| DOI | |
| Status | Udgivet - 2023 |
Bibliografisk note
Funding Information:
This study was funded by European Research Council, German Ministry of Research and Education, Academy of Finland, Finnish Medical Foundation, and the Finnish Foundation for Cardiovascular Research, the Emil Aaltonen Foundation, and the Paavo Nurmi Foundation.RBS has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme under the grant agreement No 648131, from the European Union's Horizon 2020 research and innovation programme under the grant agreement No 847770 (AFFECT-EU) and German Center for Cardiovascular Research (DZHK e.V.) (81Z1710103); German Ministry of Research and Education (BMBF 01ZX1408A) and ERACoSysMed3 (031L0239). ASH has received funding from the Academy of Finland (321356). TN has received funding from the Academy of Finland (321351), the Emil Aaltonen Foundation, and Finnish Medical Foundation, and the Finnish Foundation for Cardiovascular Research. LL has received funding from the Academy of Finland (295741). VS was supported by the Finnish Foundation for Cardiovascular research. JP was supported by the Paavo Nurmi Foundation. SKF has received funding from the German Center for Cardiovascular Research (DZHK e.V. Standort Berlin MDC) (81Z0100113) and the German Research Foundation (DFG, SFB1470).
Funding Information:
RBS has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme under the grant agreement No 648131 , from the European Union’s Horizon 2020 research and innovation programme under the grant agreement No 847770 (AFFECT-EU) and German Center for Cardiovascular Research (DZHK e.V.) ( 81Z1710103 ); German Ministry of Research and Education ( BMBF 01ZX1408A ) and ERACoSysMed3 (031L0239). ASH has received funding from the Academy of Finland ( 321356 ). TN has received funding from the Academy of Finland ( 321351 ), the Emil Aaltonen Foundation , and Finnish Medical Foundation , and the Finnish Foundation for Cardiovascular Research . LL has received funding from the Academy of Finland ( 295741 ). VS was supported by the Finnish Foundation for Cardiovascular research. JP was supported by the Paavo Nurmi Foundation . SKF has received funding from the German Center for Cardiovascular Research (DZHK e.V., Standort Berlin MDC) ( 81Z0100113 ) and the German Research Foundation (DFG, SFB1470 ).
Publisher Copyright:
© 2023 The Author(s)
ID: 347000256